Cytrellis Biosystems

Cytrellis Biosystems is a private, commercial-stage medical device company focused on the dermatology and aesthetics market. Its core innovation is the ellacor® system, an FDA-cleared device that employs a novel Micro-Coring® technology to physically remove small columns of skin, addressing moderate to severe wrinkles and skin laxity. The company has launched an updated version, ellacor® 2.0, and is led by a team with extensive experience in medical device development and commercialization. Cytrellis operates in the large and growing non-surgical aesthetic treatment market, positioning itself as a differentiated technology between energy-based devices and invasive surgery.

Proprietary Micro-Coring® technology, a mechanical, non-thermal method for removing microscopic, full-thickness columns of skin to treat laxity and wrinkles.

Cytrellis competes in the non-surgical skin tightening market against a range of technologies, including ultrasound (Ultherapy), radiofrequency (Morpheus8, Thermage), and laser-based devices. Its primary differentiation is the mechanical removal of skin micro-cores, offering a direct, non-thermal solution positioned between energy-based devices and surgical facelifts.